Form 4: Teva Pharmaceutical Industries Executive Sells Shares
Insider Transaction (Form 4)
Evan Lippman, EVP, Business Development of Teva Pharmaceutical Industries Ltd, sold 18,600 shares of common stock on August 17, 2026 for $36.57 per share.
Summary
- Open-market sale: disposed of 18,600 Ordinary Shares at $36.57 ($680,291) on August 17, 2026; holds 25,591 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $680,291 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Evan Lippman — Officer (EVP, Business Development)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Open-market sale | Ordinary Shares | 18,600 | $37 | $680.3K | 25,591 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Open-market sale (18,600 shares) |
Keywords
insider transaction, Form 4, TEVA, TEVA PHARMACEUTICAL INDUSTRIES LTD, bearish, Evan Lippman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.